https://scholars.lib.ntu.edu.tw/handle/123456789/557663
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Yang, Chih-Jen | en_US |
dc.contributor.author | Wei, Yu-Jui | en_US |
dc.contributor.author | Chang, Hsu-Liang | en_US |
dc.contributor.author | Chang, Pi-Yu | en_US |
dc.contributor.author | Tsai, Chung-Chen | en_US |
dc.contributor.author | Chen, Yen-Hsu | en_US |
dc.contributor.author | PO-REN HSUEH | en_US |
dc.date.accessioned | 2021-04-23T03:16:49Z | - |
dc.date.available | 2021-04-23T03:16:49Z | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 16841182 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/557663 | - |
dc.description.abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi | en_US |
dc.subject | Compassionate use; Coronavirus disease 2019; Remdesivir; Severe acute respiratory syndrome coronavirus 2 | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; angiotensin receptor antagonist; azithromycin; chloroquine; colchicine; convalescent plasma; corticosteroid; dipeptidyl carboxypeptidase inhibitor; favipiravir; hemoglobin; hydroxychloroquine; ibuprofen; indometacin; interferon; lopinavir plus ritonavir; placebo; remdesivir; ribavirin; tocilizumab; adenosine phosphate; alanine; antivirus agent; remdesivir; acute respiratory failure; anemia; antiviral activity; artificial ventilation; constipation; coronavirus disease 2019; drug efficacy; drug mechanism; drug withdrawal; estimated glomerular filtration rate; evidence based medicine; headache; human; hyperbilirubinemia; hypertransaminasemia; hypoalbuminemia; hypokalemia; hypotension; kidney failure; loading drug dose; lower respiratory tract infection; maculopapular rash; multicenter study (topic); nausea; nonhuman; oxygen therapy; pandemic; phase 3 clinical trial (topic); preclinical study; randomized controlled trial (topic); Review; thrombocytopenia; virus pneumonia; China; clinical trial (topic); drug effect; drug therapy; epidemiology; pandemic; Adenosine Monophosphate; Alanine; Antiviral Agents; China; Clinical Trials as Topic; COVID-19; Humans; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2 | - |
dc.title | Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review | en_US |
dc.type | review | en_US |
dc.identifier.doi | 10.1016/j.jmii.2020.09.002 | - |
dc.identifier.pmid | 33060041 | - |
dc.identifier.scopus | 2-s2.0-85092537252 | - |
dc.identifier.url | https://scholars.lib.ntu.edu.tw/handle/123456789/528152 | - |
dc.relation.journalvolume | 54 | en_US |
dc.relation.journalissue | 1 | en_US |
dc.relation.pageend | 36 | en_US |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | review | - |
item.languageiso639-1 | en | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.orcid | 0000-0002-7502-9225 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。